FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022878312> ?p ?o ?g. }

• W2022878312 endingPage "371" @default.
• W2022878312 startingPage "371" @default.
• W2022878312 abstract "Introduction: Current management of moderate/severe CD patients failing 5-ASA consists of glucocorticosteroids (GCS), resulting in a 1-year remission rate of 26%, steroid dependency, and significant toxicity. This study examined whether more aggressive induction therapy with infliximab (IFX) and azathioprine (AZA) would lead to higher remission rates, lower toxicity, and superior mucosal healing. Methods: One hundred thirty CD patients with a CDAI > 220, diagnosed within 4 years and never treated with GCS/immunomodulators/IFX, were randomized to receive either (1) top-down (TD) treatment with 3 infusions of IFX (at week 0, 2, and 6) and AZA 2 to 2.5 mg/kg per day or (2) step-up (SU) treatment with topical (budesonide 9 mg/day) or systemic (prednisone 40 mg/day) GCS, to be repeated as clinically necessary. In the TD group, relapsing patients were given repeated IFX and GCS when they failed to respond to IFX. In the SU group, AZA was added in case of repeated need for GCS or dependency and IFX was given only after failure of immunosuppression. The primary endpoints were remission (CDAI <150, no GCS) at month 6 and 12. Secondary endpoints included mean CDAI scores, mucosal healing 2 years after randomization and safety. Results: Baseline patient characteristics were similar in both groups (mean CDAI 331 TD [n = 65] vs 306 SU [n = 65]). Remission was attained in 74.5% (TD) vs 48.1% (SU) (P = .006) at 6 months and in 76.9% (TD) vs 63.8 % (SU) at 12 months (P = .15). At 6 months, 32.7% of SU patients were still receiving GCS (median dose 26 mg/day) compared with 0% for the TD group. At 12 months, 18.8% of SU patients remained on GCS (median dose 24 mg) compared with 0% in the TD group (P < .001). At 6 and 12 months 86.8% and 94.2% of patients were using immunomodulators in the TD group, compared with 40.4% and 62.5% in the SU group (P < .001). Ten of 65 (15 %) SU patients needed IFX to induce remission whereas 25/65 (38%) of patients in the TD group needed repeat IFX. Fistulas developed in 2/45 SU patients and no patients in TD. Endoscopic healing was significantly more pronounced in TD patients than in SU patients (at 2 years, ulcers were absent in 15/20 TD patients versus 3/14 SU patients, P = .002). The occurrence of serious adverse events was comparable in both groups. Conclusion: Induction therapy with IFX + AZA is superior to sequential SU therapy for reducing exposure to GCS. One third of patients treated with GCS induction therapy still require GCS at month 6, and 18.8% at 12 months. Using the TD induction strategy, long-lasting remission was achieved in 77% of patients without GCS. Our results strongly suggest that GCS therapy is not necessary for induction of remission in moderate to severely active CD." @default.
• W2022878312 created "2016-06-24" @default.
• W2022878312 creator A5012473239 @default.
• W2022878312 creator A5013059229 @default.
• W2022878312 creator A5017351016 @default.
• W2022878312 creator A5022022076 @default.
• W2022878312 creator A5032417574 @default.
• W2022878312 creator A5045465014 @default.
• W2022878312 creator A5051292857 @default.
• W2022878312 creator A5057899912 @default.
• W2022878312 creator A5066559117 @default.
• W2022878312 creator A5077220554 @default.
• W2022878312 creator A5078627834 @default.
• W2022878312 creator A5087437075 @default.
• W2022878312 date "2005-07-01" @default.
• W2022878312 modified "2023-10-17" @default.
• W2022878312 title "Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy" @default.
• W2022878312 doi "https://doi.org/10.1053/j.gastro.2005.05.064" @default.
• W2022878312 hasPublicationYear "2005" @default.
• W2022878312 type Work @default.
• W2022878312 sameAs 2022878312 @default.
• W2022878312 citedByCount "44" @default.
• W2022878312 countsByYear W20228783122019 @default.
• W2022878312 crossrefType "journal-article" @default.
• W2022878312 hasAuthorship W2022878312A5012473239 @default.
• W2022878312 hasAuthorship W2022878312A5013059229 @default.
• W2022878312 hasAuthorship W2022878312A5017351016 @default.
• W2022878312 hasAuthorship W2022878312A5022022076 @default.
• W2022878312 hasAuthorship W2022878312A5032417574 @default.
• W2022878312 hasAuthorship W2022878312A5045465014 @default.
• W2022878312 hasAuthorship W2022878312A5051292857 @default.
• W2022878312 hasAuthorship W2022878312A5057899912 @default.
• W2022878312 hasAuthorship W2022878312A5066559117 @default.
• W2022878312 hasAuthorship W2022878312A5077220554 @default.
• W2022878312 hasAuthorship W2022878312A5078627834 @default.
• W2022878312 hasAuthorship W2022878312A5087437075 @default.
• W2022878312 hasBestOaLocation W20228783121 @default.
• W2022878312 hasConcept C126322002 @default.
• W2022878312 hasConcept C141071460 @default.
• W2022878312 hasConcept C168563851 @default.
• W2022878312 hasConcept C203092338 @default.
• W2022878312 hasConcept C204243189 @default.
• W2022878312 hasConcept C2776136866 @default.
• W2022878312 hasConcept C2776760755 @default.
• W2022878312 hasConcept C2776804153 @default.
• W2022878312 hasConcept C2777138892 @default.
• W2022878312 hasConcept C2777288759 @default.
• W2022878312 hasConcept C2778260677 @default.
• W2022878312 hasConcept C2778720950 @default.
• W2022878312 hasConcept C2779134260 @default.
• W2022878312 hasConcept C2779280984 @default.
• W2022878312 hasConcept C2780252810 @default.
• W2022878312 hasConcept C29730261 @default.
• W2022878312 hasConcept C71924100 @default.
• W2022878312 hasConcept C90924648 @default.
• W2022878312 hasConceptScore W2022878312C126322002 @default.
• W2022878312 hasConceptScore W2022878312C141071460 @default.
• W2022878312 hasConceptScore W2022878312C168563851 @default.
• W2022878312 hasConceptScore W2022878312C203092338 @default.
• W2022878312 hasConceptScore W2022878312C204243189 @default.
• W2022878312 hasConceptScore W2022878312C2776136866 @default.
• W2022878312 hasConceptScore W2022878312C2776760755 @default.
• W2022878312 hasConceptScore W2022878312C2776804153 @default.
• W2022878312 hasConceptScore W2022878312C2777138892 @default.
• W2022878312 hasConceptScore W2022878312C2777288759 @default.
• W2022878312 hasConceptScore W2022878312C2778260677 @default.
• W2022878312 hasConceptScore W2022878312C2778720950 @default.
• W2022878312 hasConceptScore W2022878312C2779134260 @default.
• W2022878312 hasConceptScore W2022878312C2779280984 @default.
• W2022878312 hasConceptScore W2022878312C2780252810 @default.
• W2022878312 hasConceptScore W2022878312C29730261 @default.
• W2022878312 hasConceptScore W2022878312C71924100 @default.
• W2022878312 hasConceptScore W2022878312C90924648 @default.
• W2022878312 hasIssue "1" @default.
• W2022878312 hasLocation W20228783121 @default.
• W2022878312 hasOpenAccess W2022878312 @default.
• W2022878312 hasPrimaryLocation W20228783121 @default.
• W2022878312 hasRelatedWork W2022878312 @default.
• W2022878312 hasRelatedWork W2028694055 @default.
• W2022878312 hasRelatedWork W2105923122 @default.
• W2022878312 hasRelatedWork W2412729130 @default.
• W2022878312 hasRelatedWork W2419090247 @default.
• W2022878312 hasRelatedWork W2468906205 @default.
• W2022878312 hasRelatedWork W2624815199 @default.
• W2022878312 hasRelatedWork W3000377527 @default.
• W2022878312 hasRelatedWork W3032508331 @default.
• W2022878312 hasRelatedWork W4310872065 @default.
• W2022878312 hasVolume "129" @default.
• W2022878312 isParatext "false" @default.
• W2022878312 isRetracted "false" @default.
• W2022878312 magId "2022878312" @default.
• W2022878312 workType "article" @default.